ELOCTA® AND ALPROLIX® IN EUROPE: LONG TERM EXPERIENCE AND REAL-WORLD CASES

Sobi™ Satellite Symposium

10th Annual Congress of the European Association for Haemophilia and Allied Disorders

Paris, France

Wednesday 1 February 2017, 18:00 – 19:30, Room CDEF, Paris Marriott Rive Gauche Hotel

Dear Colleague,

On behalf of Sobi™, we would like to invite you to the Satellite Symposium which will take place on **Wednesday 1 February 2017 in Room CDEF at the Paris Marriott Rive Gauche Hotel, from 18:00 – 19:30**. We look forward to seeing you at this engaging and informative symposium.

With kind regards,

Hervé Chambost (Chair)
Professor, MD, PhD, Marseille, France

Stefan Lethagen (Co-chair)
Professor, MD, PhD, Vice President Medical & Clinical Sciences, Haemophilia, Sobi™

Agenda

18:00 – 18:10	**Welcome and Introduction**	Stefan Lethagen, Sobi™
18:10 – 18:25	**Features of Elocta® and Alprolix®**	Hervé Chambost, France
18:25 – 18:45	**How I Switched My Patients to Elocta® and Alprolix®: Real-World Cases from Germany**	Johannes Oldenburg, Germany
18:45 – 19:05	**How I Switched My Patients to Elocta® and Alprolix®: Real-World Cases from the United Kingdom**	Pratima Chowdary, United Kingdom
19:05 – 19:25	**How I Switched My Patients to Elocta®: Real-World Cases from France**	Hervé Chambost, France
19:25 – 19:30	**Closing Remarks**	Stefan Lethagen, Sobi™

For healthcare professionals only. The content of the symposium may not correspond to the guidelines in your country. Please refer to your local guidelines and prescribing information.

sobi
Pioneer in Rare Diseases

ELOCTA®▼
efmoroctocog alfa
(recombinant human coagulation factor VIII, Fc fusion protein)

ALPROLIX®▼
eftrenonacog alfa
(recombinant human coagulation factor IX, Fc fusion protein)

Sobi, Elocta and Alprolix are trademarks of Swedish Orphan Biovitrum AB (publ).
© 2016 Swedish Orphan Biovitrum AB (publ) – All rights reserved

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden
www.sobihaemophilia.com

▼This medicinal product is subject to additional monitoring
Elocta® (EMA)
Alprolix® (EMA)

Date of preparation: December 2016
PP-1931